RxDoctor Payments Data

Gloria Ethier, DO

Family Medicine · Saratoga Springs, NYNPI 1801155494

Payments from drug & device makers

$8,485in general payments, 2019–2025

Across 465 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$976
  • Amgen$949
  • GSK$867
  • AstraZeneca$757
  • Lilly USA, LLC$694
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$8,39499%
  • Education$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,485 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$77,001
Medicare patients
224
Services billed
2,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$294,866
JardianceEmpagliflozin64$92,483
FarxigaDapagliflozin Propanediol53$80,724
TrulicityDulaglutide50$72,454
EliquisApixaban31$41,404
MounjaroTirzepatide17$35,661
WegovySemaglutide16$21,569
Repatha SureclickEvolocumab21$20,380
XareltoRivaroxaban11$17,782
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,777
SynthroidLevothyroxine Sodium106$8,457
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,227
Rosuvastatin Calcium237$4,610
LivaloPitavastatin Calcium13$4,281
SymbicortBudesonide/Formoterol Fumarate13$3,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,114$316,435168 claims
Lilly USA, LLCTrulicity, Mounjaro$694$108,11667 claims
Boehringer IngelheimJardiance$404$92,48364 claims
AstraZenecaFarxiga, Symbicort$757$83,96966 claims
PfizerEliquis, Paxlovid$240$42,77148 claims
Johnson & JohnsonXarelto$185$17,78211 claims
GSKTrelegy Ellipta$867$17,77718 claims
AbbVieSynthroid$976$8,457106 claims
Kowa Pharmaceuticals America, Inc.Livalo$15$4,28113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →